Introduction The implantation of Flow-Diverter stents (FD) is an effective technic for the treatment of intracranial aneurysms but can expose to severe hemorrhagic and/or ischemic complications due to their metallic structure. CD31 is a trans-membranous protein highly expressed on the luminal surface of arteries and endowed with a contact-driven attractive effect on endothelial cells, and an inhibitory effect of platelets and leucocytes activation. The goal of this study was to evaluate, *in vitro* and *in vivo*, whether a coating with P8RI, a biomimetic peptide of CD31, could improve the biocompatibility of FD.

Methods The coating of metal pellets and Silk Vista Baby® (Balt, France) FDs with P8RI was obtained via a series of dip-coating steps, including the formation of an intermediate poly-dopamine (PDA) layer. *In vitro*, the adhesion of endothelial cells under different conditions was tested on uncoated and coated metal pellets (PDA alone and PDA with P8RI), and their thrombogenic and inflammatory phenotype were monitored. *In vivo*, we used a validated elastase-induced saccular carotid aneurysm model in rabbits, separated into three groups: a test group with P8RI-coated FD (P8RI), and two control groups with unmodified FD (UFD) and PDA-coated FD (PDA). Angiographic results were evaluated at 1 and 3 months. Histological, scanning electron and multiphoton microscopy analyses were assessed at 1 month. Patency of covered branches was also evaluated on FD placed in the abdominal aorta covering lumbar arteries.

Results *In vitro*, P8RI coating promotes adhesion of endothelial cells and induces a less inflammatory and less thrombogenic endothelial cell phenotype. *In vivo*, 25 aneurysms were created in 25 rabbits and were treated with 7 UFD, 9 PDA and 9 P8RI FDs. There was no significant difference in complete occlusion rate. Histological and microscopy analyses at 1 month showed that the coating with the P8RI peptide improved the integration of the device at the blood vessel interface and the quality of its endothelialization (figure 1). All covered arteries remained patent with no stenosis in all 3 groups.

Conclusion P8RI coating of FD improves biocompatibility and healing process of aneurysm treatment. These results are a crucial step towards a translation to clinical, this technology could be extended also to other intra-arterial devices used in interventional neuroradiology.

Disclosures J. Cortese: 1; C; Fondation pour la Recherche Médicale (DEA20170637766). C. Rasser: None. G. Even: None. C. Choqueux: None. S. Bardet: None. J. Caroff: None. L. Spelle: None. G. Caligiuri: None. A. Rouchaud: None.

0-014

DOUBLE STENT-ASSISTED COILING OF INTRACRANIAL ANEURYSMS WITH THE NEUROFORM ATLAS STENT IN Y AND X CONFIGURATIONS: IMMEDIATE AND MIDTERM ANGIOGRAPHIC AND CLINICAL FOLLOW-UP

G Ciccio*, T Robert, R Fahed, S Smajda, R Blanc, M Piotin. *NRI, Fondation Rothschild, Paris, France*

10.1136/neurintsurg-2019-SNIS.14

Object Self-expandable stents have broadened the spectrum of endovascular treatment of intracranial aneurysms. However procedures involving double stenting in Y or X configuration carry a relatively high risk of procedural complications. The Neuroform ATLAS, the evolution of Neuroform EZ, is a

nitinol self-expanding hybrid/open-cell stent, which can be delivered through a low-profile 0.017 inch catheter. We present our experience in the treatment of intracranial aneurysms with this stent in Y and X configuration.

Methods We prospectively maintained a database from consecutive patients who underwent double stent-assisted coiling with Neuroform ATLAS from July 2015 to February 2019. Clinical and angiographic results were analyzed.

Results Fifty-six patients harboring 56 aneurysms were treated with double stenting: 53 'Y' configurations, 3 'X' configurations. Deployment was successful in all but one case of Y stenting, which was prematurely interrupted because of aneurysm perforation. Post-treatment control angiography showed complete occlusion in 33 cases (60%), neck remnant in 8 cases (14.5%) and incomplete occlusion in 14 cases (25.4%). The overall symptomatic peri-procedural complication rate was 14%. The overall morbidity rate was 7.1%. Thirty-seven aneurysms underwent follow-up (66%, mean duration: 16 months): 32 aneurysms (86.4%) were completely occluded, 3 aneurysms (8.1%) had a neck remnant, and 2 aneurysms (5.4%) were incompletely occluded.

Conclusion The Neuroform ATLAS is an effective device for treatment of complex intracranial aneurysms, allowing good conformability, high level of navigability and easy mesh crossing to perform Y or X stenting procedures. The rate of procedural complications remains non negligible, and indication of double-stenting procedure should always be discussed in a multidisciplinary meeting.

Disclosures G. Ciccio*: None. T. Robert: None. R. Fahed: None. S. Smajda: None. R. Blanc: None. M. Piotin: None.

0-015

COMPARISON OF IMAGE QUALITY OF LIQUID EMBOLIC AGENTS

J Mason*. *Radiology, Baylor College of Medicine, Houston, TX*

10.1136/neurintsurg-2019-SNIS.15

Introduction Liquid embolic agents (LEAs) play a major role in the treatment of cerebral arteriovenous malformations (AVMs) and dural arteriovenous fistulas (DAVFs). Injection under subtracted fluoroscopy (Blank Road Map, RM) is the preferred technique, especially when using ethylene-vinyl-copolymer based agents. Optimal visual control during injection is crucially important to avoid catheter entrapment or non-target embolization and is strongly dependent on Road Map (RM) quality. Available LEAs differ in their radiopacity the main factor for visual control. We present a comparison study of radiographic visibility of various LEAs using a novel injectable angiographic phantom.

Methods An injectable angiographic phantom was designed with parallel tubings between 313 and 1000 micron. Under RM, eight radiopaque liquid agents were injected: Onyx®18,34 (Medtronic, Dublin, Ireland), SQUID®12,18 (Emboflu, Fribourg, Switzerland), PHIL®25,30 (MicroVention, Tustin, CA, USA), Trufill® (NBCA) (Cordis Neurovascular, Miami, FL, USA) 30% dilution and Omnipaque®300 (GE Healthcare, Chicago, IL, USA). The phantom was imaged using an Artis Zeego system (Siemens Healthineers, Erlangen, Germany) with consistent settings ('RM Glue', RM K40 EA3, 15 p/s). Image analysis was performed with *ImageJ* (NIH, Bethesda, Maryland) and *Matlab* (MathWorks, Inc., Natick, MA). Contrast resolution (CR) was evaluated as a contrast to noise ratio